Safety of rituximab therapy during the first trimester of pregnancy: a case history
Authors:
- Eva KimbyEKEva Kimby
- Asgerdur SverrisdottirASAsgerdur Sverrisdottir
- Göran ElinderGEGöran Elinder
- 8 March 2004
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 72 (4) , 292-295
Abstract
The optimal treatment of non‐Hodgkin's lymphoma (NHL) during pregnancy is currently undefined. The potential teratogenic effects of conventional chemotherapy preclude its use during the first trimester of pregnancy. We report the case of a pregnant woman with relapsed indolent follicular NHL who was treated with rituximab (unintentionally) during the first trimester. The treatment stabilised the disease. Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab. Data of using rituximab during pregnancy are scarce, but the present case shows that rituximab may be one option for treatment of NHL in early pregnancy.Keywords
This publication has 7 references indexed in Scilit:
- RituximabDrugs, 2003
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphomaAnnals of Oncology, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998